Somatostatin Analogs Market

Report Highlights

The scope of this report covers the different types of somatostatin analogs, impact of COVID-19 on the market, and therapies used to treat the various diseases such as, acromegaly, neuroendocrine tumors, carcinoid syndrome, and cushing syndrome. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each by type, application, route of administration, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional somatostatin analogs markets; it explains the major market drivers of the global somatostatin analogs industry, current trends within the industry, major applications, and the regional dynamics of the global somatostatin analogs market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the Global Somatostatin Analogs Market.

Report Includes

• 41 tables and 49 figures
• An up-to-date analysis of the global somatostatin analogs market.
• Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
• Estimation of market size and revenue forecast for global somatostatin analogs market, and corresponding market share analysis by type, application, route of administration, end-user, and region.
• Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for somatostatin analogs, identification of the companies that are best positioned to meet this demand.
• In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
• Identification of promising new formulations and products still in the development and testing stages, and their probability of successful commercial launch within the next five years.
• Impact of COVID-19 on the somatostatin analogs market as compared to overall global economy.
• Insight into the growth development strategies of major somatostatin analogs manufacturers and their key competitive landscape
• Descriptive company profiles of the leading market participants, including Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Dauntless Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and others.

Summary

Somatostatin analogs are man-made drugs which are used as a first line treatment for various rare diseases such as, acromegaly, neuroendocrine tumors (NETs), carcinoid syndrome, and cushing syndrome. Besides this, somatostatin analogs are also used to treat VIPoma's, glucagonomas, and GH-secreting tumors. Somatostatin analogs are the drugs which prohibit the secretion of hormone in the body. Somatostatin analogs act by reducing secretion of various growth hormones and serotonin. The secretion of substantial number of hormones by NET leads to carcinoid syndrome. This further controls the symptoms of carcinoid syndrome since somatostatin analogs are the most possible treatment for people suffering with carcinoid syndrome.